Health ❯ Healthcare ❯ Drug Safety

Side Effects

Adverse Reactions Patient Tolerance Clinical Study Results Amyloid-Related Imaging Abnormalities Gastrointestinal Issues GLP-1 Drugs Ocular Issues Patient Dropout Rates Patient Warnings Differentiation Syndrome Clinical Trials Risks of Tirzepatida Hypoglycemia Clinical Warnings ARCALYST Safety Information Clinical Safety Profiles Clinical Trial Side Effects

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Amylyx plans a year‑end FDA filing that could lead to a 2027 launch funded by a new equity offering.

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Cannabis Extract VER-01 Eases Chronic Low Back Pain in Phase 3 Trial

Pumitamig Shows High Response in First-Line Small Cell Lung Cancer Phase 2